IP Library › Patent Application 13454658
Patent Application
App. No. 13/454,658

DIMENSIONAL ANALYSIS OF SACCHARIDE CONJUGATES WITH GPC & SEC MALS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/454,658
Abstract

GPC (gel permeation chromatography) and size exclusion chromatography with detection by multi-angle light-scattering photometry (SEC-MALS) can be used to accurately measure molecular size and molar mass, respectively, of saccharide conjugates. The invention provides (a) a process for measuring the molecular size of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by GPC, and (b) a process for measuring the molar mass of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by SEC-MALS.

Claims (20)

1 . A composition comprising a conjugate of a capsular saccharide from serogroup W135 Neisseria meningitidis , wherein the molecular size of the conjugate is 68.7±20% Å and/or the molar mass of the conjugate is 110.1±20% kDa.

2 . The composition of claim 1 further comprising a conjugate of a capsular saccharide from serogroup A Neisseria meningitidis.

3 . The composition of claim 2 , wherein the conjugate of the capsular saccharide from serogroup A Neisseria meningitidis has a molecular size of 57.1±20% Å and/or a molar mass of 88.5±20% kDa.

4 . The composition of claim 1 further comprising a conjugate of a capsular saccharide from serogroup C Neisseria meningitidis.

5 . The composition of claim 4 , wherein the conjugate of the capsular saccharide from serogroup C Neisseria meningitidis has a molecular size of 57.0±20% Å and/or a molar mass of 85.2±20% kDa.

6 . The composition of claim 1 further comprising a conjugate of a capsular saccharide from serogroup Y Neisseria meningitidis.

7 . The composition of claim 6 , wherein the conjugate of the capsular saccharide from serogroup Y Neisseria meningitidis has a molecular size of 63.3±20% Å and/or a molar mass of the conjugate is 84.7±20% kDa.

8 . The composition of claim 1 , further comprising a conjugate of a capsular saccharide from serogroup A Neisseria meningitidis with a molecular size of 57.1±20% Å and/or a molar mass of 88.5±20% kDa; a conjugate of a capsular saccharide from serogroup C Neisseria meningitidis with a molecular size of 57.0±20% Å and/or a molar mass of 85.2±20% kDa; and a conjugate of a capsular saccharide from serogroup Y Neisseria meningitidis with a molecular size of 63.3±20% Å and/or a molar mass of 84.7±20% kDa.

9 . A composition comprising a conjugate of a capsular saccharide from serogroup Y Neisseria meningitidis , wherein the molecular size of the conjugate is 63.3±20% Å and/or the molar mass of the conjugate is 84.7±20% kDa.

10 . The composition of claim 9 further comprising a conjugate of a capsular saccharide from serogroup A Neisseria meningitidis.

11 . The composition of claim 10 , wherein the conjugate of the capsular saccharide from serogroup A Neisseria meningitidis has a molecular size of 57.1±20% Å and/or the molar mass of the conjugate is 88.5±20% kDa.

12 . The composition of claim 9 further comprising a conjugate of a capsular saccharide from serogroup C Neisseria meningitidis.

13 . The composition of claim 12 , wherein the conjugate of the capsular saccharide from serogroup C Neisseria meningitidis has a molecular size of 57.0±20% Å and/or a molar mass of 85.2±20% kDa.

14 . The composition of claim 9 further comprising a conjugate of a capsular saccharide from serogroup W135 Neisseria meningitidis.

15 . The composition of claim 14 , wherein the conjugate of the capsular saccharide from serogroup W135 Neisseria meningitidis has a molecular size of 68.7±20% Å and/or a molar mass of 110.1±20% kDa.

16 . A composition comprising conjugates of capsular saccharides from serogroups A, C, W135, and Y Neisseria meningitidis , wherein the conjugate of the capsular saccharide from serogroup C Neisseria meningitidis has a molecular size of 57.0±20% Å and/or a molar mass of 85.2±20% kDa.

17 . The composition of claim 16 , wherein the conjugate of the capsular saccharide from serogroup A Neisseria meningitidis has a molecular size of 57.1±20% Å and/or the molar mass of the conjugate is 88.5±20% kDa.

18 . The composition of claim 16 , wherein the conjugate of the capsular saccharide from serogroup W135 Neisseria meningitidis has a molecular size of 68.7±20% Å and/or a molar mass of 110.1±20% kDa.

19 . The composition of claim 16 , wherein the conjugate of the capsular saccharide from serogroup Y Neisseria meningitidis has a molecular size of 63.3±20% Å and/or a molar mass of 84.7±20% kDa.

20 . A process for measuring the molecular size of a conjugate of a capsular saccharide from Neisseria meningitidis within a sample, comprising a step of size exclusion chromatography with detection by multi-angle light-scattering photometry.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2016
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 040254/0677 →